---
title: "FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's"
description: "FDA approval for DexCom's Stelo opens up continuous glucose monitoring to non-insulin-dependent diabetics. The competitive pricing and potential HSA benefits make it a significant player in the CGM sp"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/109388390.md"
published_at: "2024-03-06T21:50:37.000Z"
---

# FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's

> FDA approval for DexCom's Stelo opens up continuous glucose monitoring to non-insulin-dependent diabetics. The competitive pricing and potential HSA benefits make it a significant player in the CGM space. The market for Stelo offers substantial opportunities beyond the core insulin therapy markets. DexCom and Abbott are expected to reach over 100 million individuals in their next growth phase.

Tuesday, the FDA approved **DexCom Inc’s** (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM).

The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for anyone 18 years and older who does not use insulin.

**William Blair** states that although initial pricing details for Stelo are undisclosed, it is anticipated to be competitive with **Abbott Laboratories** (NYSE:ABT) current cash-pay price of approximately $80 per month. 

DexCom, historically priced slightly higher than Abbott, is estimated at $90 per month, with potential cost reductions for patients through HSA benefits based on their tax bracket.

The analyst notes the FDA’s suggestion of requiring prior iCGM (integrated Continuous Glucose Monitoring) approval for OTC devices sets a high regulatory standard, favoring established players like DexCom and Abbott. 

Meeting the criteria for iCGM accuracy is expensive and time-consuming, creating a significant hurdle for potential competitors.

The market for Stelo, catering to non-insulin-dependent diabetics (over 25 million patients), offers substantial opportunities beyond the core insulin therapy markets, William Blair highlights. 

With potential applications for prediabetics and metabolic health, the expanding prevalence of obesity and a growing number of type 2 diabetics contribute to a rising demand for CGM technology.

The combined market potential for DexCom and Abbott is estimated to reach over 100 million individuals, including prediabetics and potential metabolic health users, as the companies embark on their next growth phase.

Abbott has considered introducing Lingo, a product potentially receiving OTC approval, focusing on health and wellness. 

However, it’s worth highlighting that Stelo, at least in the short term, stands out as the sole OTC device designed specifically for type 2 non-insulin-dependent diabetics.

**Price Action:** DXCM shares closed higher by 7.83% at $131.32 on the last check Wednesday.

*Photo via Company*

### Related Stocks

- [DXCM.US - DexCom](https://longbridge.com/en/quote/DXCM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 德康医疗｜8-K：2025 财年 Q4 营收 12.6 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275807118.md) |
| 德康医疗｜8-K：2025 财年 Q4 营收 12.6 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/272268978.md) |
| 爱美医疗｜10-K：2025 财年营收 6.34 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276485511.md) |
| PTC Therap｜8-K：2025 财年 Q4 营收 1.65 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276378877.md) |
| 亚德诺｜8-K：2026 财年 Q1 营收 31.6 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276224711.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.